A research team based out of both University of Iowa and the University of Georgia discovered that their single-dose, intranasal COVID-19 vaccine fully protects mice against lethal COVID-19 infection. Apparently, this early-stage vaccine also blocks animal-to-animal transmission of the virus. With results recently published in the peer-reviewed journal of Science Advances, an operating premise here—and opportunity for commercial partner—is that a new, easier to administer vaccine could help accelerate global vaccination against SARS-CoV-2, the virus behind COVID-19. One of the co-investigators has also set up a startup venture to commercialize the investigational vaccine. Could the upside for an easy to administer, safe, and effective COVID-19 vaccine be worth the wait for the right investor(s)?
Although the existing batch of what TrialSite called COVID-19 vaccine 1.0 products appear to work well (although safety reports are contributing to vaccine hesitancy), the world’s population continues to go unvaccinated. Thus the co-lead investigator for this effort, Dr. Paul McCray, professor of pediatrics-pulmonary medicine and microbiology and immunology at the Unive...
Note: If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).